Antineoplaston Therapy (CPB 0240, reviewed 2026-04-13)
Summary
Aetna considers antineoplaston therapy (auto-urine therapy) experimental, investigational, or unproven because the effectiveness of these approaches has not been established. The following services associated with antineoplaston therapy are also listed as experimental, investigational, or unproven: ancillary diagnostic laboratory, x-rays, MRI or CT scans done to monitor the therapy; infusion pump and intravenous supplies for use with the infusion pump; placement of Hickman catheter; and oral antineoplaston therapy or associated physician services for administering and monitoring oral antineoplaston treatment. Antineoplaston therapy is not approved by the Food and Drug Administration (FDA) for any indication.
Get alerts when payers change rules like this one
We check Aetna and other payers every day and email you when a change matches your specialty and state.